tiprankstipranks
Advertisement
Advertisement

MRKR Stock Latest News

Marker Therapeutics: Buy Rating Reaffirmed with Unchanged $8 Price Target on Optimism for MT-601 Data and Pivotal Pathway
RatingsMarker Therapeutics: Buy Rating Reaffirmed with Unchanged $8 Price Target on Optimism for MT-601 Data and Pivotal Pathway
3d ago
MRKR
Buy Rating Reaffirmed on Marker Therapeutics as Clinical Milestones Near; $8 Price Target Maintained
PremiumRatings
Buy Rating Reaffirmed on Marker Therapeutics as Clinical Milestones Near; $8 Price Target Maintained
1M ago
MRKR
MRKR Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
MRKR Upcoming Earnings Report: What to Expect?
2M ago
MRKR
Marker Therapeutics Shareholders Approve Governance and Capital Changes
PremiumCompany Announcements
Marker Therapeutics Shareholders Approve Governance and Capital Changes
2M ago
8K
MRKR
Advancing Multi-Antigen Cell Therapies: Buy Rating on Marker Therapeutics Ahead of Key 2Q26 FDA Catalyst
PremiumRatings
Advancing Multi-Antigen Cell Therapies: Buy Rating on Marker Therapeutics Ahead of Key 2Q26 FDA Catalyst
3M ago
MRKR
Marker Therapeutics Highlights Strong MT-601 Data and Prepares for Key 2026 Milestones
PremiumCompany AnnouncementsMarker Therapeutics Highlights Strong MT-601 Data and Prepares for Key 2026 Milestones
4M ago
MRKR
Marker Therapeutics: Upcoming MT-601 and MT-401 Catalysts Support Buy Rating and $8 Target on Favorable Risk-Reward
Premium
Ratings
Marker Therapeutics: Upcoming MT-601 and MT-401 Catalysts Support Buy Rating and $8 Target on Favorable Risk-Reward
4M ago
MRKR
Marker Therapeutics reports FY25 EPS (79c), two estimates (94c)
Premium
The Fly
Marker Therapeutics reports FY25 EPS (79c), two estimates (94c)
4M ago
MRKR
Marker Therapeutics (MRKR) Q4 Earnings Cheat Sheet
PremiumPre-Earnings
Marker Therapeutics (MRKR) Q4 Earnings Cheat Sheet
4M ago
MRKR
Marker Therapeutics Sets Date for 2026 Annual Meeting
PremiumCompany Announcements
Marker Therapeutics Sets Date for 2026 Annual Meeting
5M ago
8K
MRKR
Marker announces Baylor’s TACTOPS study featured on Good Morning America
PremiumThe Fly
Marker announces Baylor’s TACTOPS study featured on Good Morning America
5M ago
MRKR
Validating Marker Therapeutics’ MAR-T Platform in Pancreatic Cancer: MT-601 Upside Supports Buy Rating and $10 Target
PremiumRatings
Validating Marker Therapeutics’ MAR-T Platform in Pancreatic Cancer: MT-601 Upside Supports Buy Rating and $10 Target
6M ago
MRKR
Marker Therapeutics announces publication on MAR-T cells in pancreatic cancer
PremiumThe FlyMarker Therapeutics announces publication on MAR-T cells in pancreatic cancer
6M ago
MRKR
Marker Therapeutics initiated with a Buy at H.C. Wainwright
Premium
The Fly
Marker Therapeutics initiated with a Buy at H.C. Wainwright
7M ago
MRKR
Marker Therapeutics Reports Q3 2025 Financial Results
Premium
Company Announcements
Marker Therapeutics Reports Q3 2025 Financial Results
8M ago
MRKR
Marker Therapeutics Announces Positive APOLLO Study Results and Strategic Advances
PremiumCompany Announcements
Marker Therapeutics Announces Positive APOLLO Study Results and Strategic Advances
8M ago
MRKR
Marker Therapeutics reports Q3 EPS (12c) vs (26c) last year
PremiumThe Fly
Marker Therapeutics reports Q3 EPS (12c) vs (26c) last year
8M ago
MRKR
Marker Therapeutics Strengthens Board with New Appointment
PremiumCompany Announcements
Marker Therapeutics Strengthens Board with New Appointment
8M ago
MRKR
Marker Therapeutics appoints Penkus Corzo to board of directors
PremiumThe Fly
Marker Therapeutics appoints Penkus Corzo to board of directors
8M ago
MRKR
Marker Therapeutics’ Innovative Approach in AML and MDS Treatment: A Study Update
PremiumCompany AnnouncementsMarker Therapeutics’ Innovative Approach in AML and MDS Treatment: A Study Update
8M ago
MRKR
Marker Therapeutics’ MT-601 Study: A Promising Step in Lymphoma Treatment
Premium
Company Announcements
Marker Therapeutics’ MT-601 Study: A Promising Step in Lymphoma Treatment
8M ago
MRKR
Marker Therapeutics Advances Off-the-Shelf T Cell Therapy with First Patient Treatment
Premium
Company Announcements
Marker Therapeutics Advances Off-the-Shelf T Cell Therapy with First Patient Treatment
9M ago
MRKR

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >